Pheochromocytoma: Current Approaches and Future Directions

Fränkel, 1886, Ein Fall von doppelseitigem, völlig latent verlaufenen Nebennierentumor und gleichzeitiger Nephritis mit Veränderungen am Circulationsapparat und Retinitis, Arch Pathol Anat Physiol Klin Med, 103, 244, 10.1007/BF01938677

Classics in oncology, 1984, A case of bilateral completely latent adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis: Felix Frankel, 1886, CA Cancer J Clin, 34, 93, 10.3322/canjclin.34.2.93

Stein, 1991, A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution's experience, Medicine (Baltimore), 70, 46, 10.1097/00005792-199101000-00004

Mantero, 2000, A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology, J Clin Endocrinol Metab, 85, 637

Sidhu, 2002, Changing pattern of adrenalectomy at a tertiary referral centre 1970–2000, ANZ J Surg, 72, 463, 10.1046/j.1445-2197.2002.02454.x

Bravo, 1984, Current concepts. Pheochromocytoma: Diagnosis, localization and management, N Engl J Med, 311, 1298, 10.1056/NEJM198411153112007

Dluhy, 2002, Pheochromocytoma—death of an axiom, N Engl J Med, 346, 1486, 10.1056/NEJM200205093461911

Neumann, 2002, Germ-line mutations in nonsyndromic pheochromocytoma, N Engl J Med, 346, 1459, 10.1056/NEJMoa020152

Amar, 2005, Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma, J Clin Endocrinol Metab, 90, 2110, 10.1210/jc.2004-1398

Manger, 2005, The vagaries of pheochromocytomas, Am J Hypertens, 18, 1266, 10.1016/j.amjhyper.2005.06.026

Manger, 1996, Clinical and Experimental Pheochromocytoma, 1

Baguet, 2004, Circumstances of discovery of phaeochromocytoma: A retrospective study of 41 consecutive patients, Eur J Endocrinol, 150, 681, 10.1530/eje.0.1500681

Pacak, 2001, Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma, Ann Intern Med, 134, 315, 10.7326/0003-4819-134-4-200102200-00016

Alderazi, 2005, Phaeochromocytoma: Current concepts, Med J Aust, 183, 201, 10.5694/j.1326-5377.2005.tb06997.x

Manger, 2006, An overview of pheochromocytoma: History, current concepts, vagaries, and diagnostic challenges, Ann N Y Acad Sci, 1073, 1, 10.1196/annals.1353.001

Young, 1995, Spells: In search of a cause, Mayo Clin Proc, 70, 757, 10.4065/70.8.757

Mannelli, 1999, Pheochromocytoma in Italy: A multicentric retrospective study, Eur J Endocrinol, 141, 619, 10.1530/eje.0.1410619

Zelinka, 2001, Diminished circadian blood pressure rhythm in patients with asymptomatic normotensive pheochromocytoma, Physiol Res, 50, 631

Herrera, 1991, Incidentally discovered adrenal tumors: An institutional perspective, Surgery, 110, 1014

Hedeland, 1968, On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes, Acta Med Scand, 184, 211, 10.1111/j.0954-6820.1968.tb02445.x

Bouloux, 1995, Investigation of phaeochromocytoma, Clin Endocrinol (Oxf), 43, 657, 10.1111/j.1365-2265.1995.tb00531.x

Kloos, 1995, Incidentally discovered adrenal masses, Endocr Rev, 16, 460

Weismann, 2006, A dangerous liaison—pheochromocytoma in patients with malignant disease, Ann Surg Oncol, 13, 1696, 10.1245/s10434-006-9184-8

Lenert, 2001, Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy, Surgery, 130, 1060, 10.1067/msy.2001.118369

Adler, 2007, Isolated adrenal mass in patients with a history of cancer: Remember pheochromocytoma, Ann Surg Oncol, 14, 2358, 10.1245/s10434-007-9426-4

Grumbach, 2003, Management of the clinically inapparent adrenal mass (“incidentaloma”), Ann Intern Med, 138, 424, 10.7326/0003-4819-138-5-200303040-00013

Mitchell, 2007, Adrenal masses in the cancer patient: Surveillance or excision, The Oncologist, 12, 168, 10.1634/theoncologist.12-2-168

Amar, 2005, Genetic testing in pheochromocytoma or functional paraganglioma, J Clin Oncol, 23, 8812, 10.1200/JCO.2005.03.1484

Astuti, 2001, Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma, Am J Hum Genet, 69, 49, 10.1086/321282

Niemann, 2000, Mutations in SDHC cause autosomal dominant paraganglioma, type 3, Nat Genet, 26, 268, 10.1038/81551

Baysal, 2000, Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma, Science, 287, 848, 10.1126/science.287.5454.848

Mannelli, 2007, Genetics and biology of pheochromocytoma, Exp Clin Endocrinol Diabetes, 115, 160, 10.1055/s-2007-970407

Walther, 1999, Pheochromocytoma: Evaluation, diagnosis, and treatment, World J Urol, 17, 35, 10.1007/s003450050102

Lenders, 2005, Phaeochromocytoma, Lancet, 366, 665, 10.1016/S0140-6736(05)67139-5

Maher, 1990, Clinical features and natural history of von Hippel-Lindau disease, Q J Med, 77, 1151, 10.1093/qjmed/77.2.1151

Friedrich, 1999, von Hippel-Lindau syndrome. A pleomorphic condition, Cancer, 86, 2478, 10.1002/(SICI)1097-0142(19991201)86:11+<2478::AID-CNCR4>3.0.CO;2-5

Maher, 1997, von Hippel-Lindau disease, Medicine (Baltimore), 76, 381, 10.1097/00005792-199711000-00001

Linehan, 1995, Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer, JAMA, 273, 564, 10.1001/jama.1995.03520310062031

Filling-Katz, 1991, Central nervous system involvement in von Hippel-Lindau disease, Neurology, 41, 41, 10.1212/WNL.41.1.41

Choyke, 1995, von Hippel-Lindau disease: Genetic, clinical, and imaging features, Radiology, 194, 629, 10.1148/radiology.194.3.7862955

Walther, 1999, Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: Comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma, J Urol, 162, 659, 10.1097/00005392-199909010-00004

Lonser, 2003, von Hippel-Lindau disease, Lancet, 361, 2059, 10.1016/S0140-6736(03)13643-4

Brauch, 1997, Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene, J Clin Endocrinol Metab, 82, 4101

van der Harst, 1998, Germline mutations in the vhl gene in patients presenting with phaeochromocytomas, Int J Cancer, 77, 337, 10.1002/(SICI)1097-0215(19980729)77:3<337::AID-IJC5>3.0.CO;2-P

Eisenhofer, 2001, Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes, J Clin Endocrinol Metab, 86, 1999, 10.1210/jcem.86.5.7496

Easton, 1989, The clinical and screening age-at-onset distribution for the MEN-2 syndrome, Am J Hum Genet, 44, 208

Ponder, 1988, Risk estimation and screening in families of patients with medullary thyroid carcinoma, Lancet, 1, 397, 10.1016/S0140-6736(88)91191-9

Gagel, 1988, The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience, N Engl J Med, 318, 478, 10.1056/NEJM198802253180804

Modigliani, 1995, Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group, J Intern Med, 238, 363, 10.1111/j.1365-2796.1995.tb01211.x

Bryant, 2003, Pheochromocytoma: The expanding genetic differential diagnosis, J Natl Cancer Inst, 95, 1196, 10.1093/jnci/djg024

Plouin, 2006, The genetic basis of pheochromocytoma: Who to screen and how?, Nat Clin Pract Endocrinol Metab, 2, 60, 10.1038/ncpendmet0097

Cantor, 1982, Neurofibromatosis, phaeochromocytoma, and somatostatinoma, Br Med J (Clin Res Ed), 285, 1618, 10.1136/bmj.285.6355.1618

Zhu, 2001, Neurofibromin, a tumor suppressor in the nervous system, Exp Cell Res, 264, 19, 10.1006/excr.2000.5138

Machens, 2006, Risk-oriented approach to hereditary adrenal pheochromocytoma, Ann N Y Acad Sci, 1073, 417, 10.1196/annals.1353.045

Gimenez-Roqueplo, 2006, Phaeochromocytoma, new genes and screening strategies, Clin Endocrinol (Oxf), 65, 699, 10.1111/j.1365-2265.2006.02714.x

Brouwers, 2006, High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: Implications for genetic testing, J Clin Endocrinol Metab, 91, 4505, 10.1210/jc.2006-0423

Benn, 2006, Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes, J Clin Endocrinol Metab, 91, 827, 10.1210/jc.2005-1862

Mannelli, 2007, Genetic screening for pheochromocytoma: Should SDHC gene analysis be included?, J Med Genet, 44, 586, 10.1136/jmg.2007.051045

Neumann, 2004, Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations, JAMA, 292, 943, 10.1001/jama.292.8.943

Martin, 2007, The genetics of paragangliomas: A review, Clin Otolaryngol, 32, 7, 10.1111/j.1365-2273.2007.01378.x

Benn, 2006, Genetic testing in pheochromocytoma- and paraganglioma-associated syndromes, Ann N Y Acad Sci, 1073, 104, 10.1196/annals.1353.011

Arnaldi, 2000, Adrenal incidentaloma, Braz J Med Biol Res, 33, 1177, 10.1590/S0100-879X2000001000007

Kudva, 2003, Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: The Mayo Clinic experience, J Clin Endocrinol Metab, 88, 4533, 10.1210/jc.2003-030720

Sawka, 2003, A comparison of biochemical tests for pheochromocytoma: Measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines, J Clin Endocrinol Metab, 88, 553, 10.1210/jc.2002-021251

Smythe, 1992, Biochemical diagnosis of pheochromocytoma by simultaneous measurement of urinary excretion of epinephrine and norepinephrine, Clin Chem, 38, 486, 10.1093/clinchem/38.4.486

Harding, 2005, Potential pitfalls in the diagnosis of phaeochromocytoma, Med J Aust, 182, 637, 10.5694/j.1326-5377.2005.tb06852.x

Lenders, 2002, Biochemical diagnosis of pheochromocytoma: Which test is best?, JAMA, 287, 1427, 10.1001/jama.287.11.1427

Sawka, 2004, A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma, BMC Endocr Disord, 4, 2, 10.1186/1472-6823-4-2

Eisenhofer, 2003, Biochemical diagnosis of pheochromocytoma: How to distinguish true- from false-positive test results, J Clin Endocrinol Metab, 88, 2656, 10.1210/jc.2002-030005

Sjoberg, 1992, The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls, Arch Intern Med, 152, 1193, 10.1001/archinte.1992.00400180061009

Elliott, 1988, Reduced specificity of the clonidine suppression test in patients with normal plasma catecholamine levels, Am J Med, 84, 419, 10.1016/0002-9343(88)90261-6

Lawrence, 1970, Glucagon and pheochromocytoma, Ann Intern Med, 73, 852, 10.7326/0003-4819-73-5-852

Lawrence, 1967, Glucagon provocative test for pheochromocytoma, Ann Intern Med, 66, 1091, 10.7326/0003-4819-66-6-1091

Apgar, 1951, Pheochromocytoma. Anesthetic management during surgical treatment, AMA Arch Surg, 62, 634, 10.1001/archsurg.1951.01250030644004

Plouin, 2001, Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: Analysis of 165 operations at a single center, J Clin Endocrinol Metab, 86, 1480

Kinney, 2002, Perioperative management of pheochromocytoma, J Cardiothorac Vasc Anesth, 16, 359, 10.1053/jcan.2002.124150

Shulkin, 2006, Current trends in functional imaging of pheochromocytomas and paragangliomas, Ann N Y Acad Sci, 1073, 374, 10.1196/annals.1353.041

Bravo, 1991, Pheochromocytoma: New concepts and future trends, Kidney Int, 40, 544, 10.1038/ki.1991.244

Bravo, 1994, Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma, Endocr Rev, 15, 356, 10.1210/edrv-15-3-356

Goldstein, 1999, Clinical experience over 48 years with pheochromocytoma, Ann Surg, 229, 755, 10.1097/00000658-199906000-00001

Maurea, 1996, Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison, Q J Nucl Med, 40, 365

Lumachi, 2006, Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: A prospective study, Nucl Med Commun, 27, 583, 10.1097/00006231-200607000-00006

Maurea, 1993, Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: Comparison with CT and MRI, J Nucl Med, 34, 173

Lebuffe, 2005, The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas, Anaesthesia, 60, 439, 10.1111/j.1365-2044.2005.04156.x

Takahashi, 1989, Effectiveness of long-acting nifedipine in pheochromocytoma, Jpn Heart J, 30, 751, 10.1536/ihj.30.751

Van Der Horst-Schrivers, 2006, Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas—experience and meta-analysis, Anticancer Res, 26, 1599

Ilias, 2003, Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma, J Clin Endocrinol Metab, 88, 4083, 10.1210/jc.2003-030235

Fujita, 2000, Use of fusion images of I-131 metaiodobenzylguanidine, SPECT, and magnetic resonance studies to identify a malignant pheochromocytoma, Clin Nucl Med, 25, 440, 10.1097/00003072-200006000-00010

Shapiro, 1995, Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: A personal overview and concluding remarks, Q J Nucl Med, 39, 150

Shulkin, 1999, Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET, Radiology, 212, 35, 10.1148/radiology.212.1.r99jl3035

Neumann, 1996, Malignant pheochromocytoma of the anterior mediastinum: PET findings with [18F]FDG and 82Rb, J Comput Assist Tomogr, 20, 312, 10.1097/00004728-199603000-00028

Shulkin, 1992, PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma, J Nucl Med, 33, 1125

Timmers, 2007, Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma, J Clin Oncol, 25, 2262, 10.1200/JCO.2006.09.6297

Esfandiari, 2006, Multimodality imaging of malignant pheochromocytoma, Clin Nucl Med, 31, 822, 10.1097/01.rlu.0000247734.67566.0a

Bravo, 2003, Pheochromocytoma: State-of-the-art and future prospects, Endocr Rev, 24, 539, 10.1210/er.2002-0013

Schütler, 1995, [Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery], Anasthesiol Intensivmed Notfallmed Schmerzther, 30, 341

Khorram-Manesh, 2005, Long-term outcome of a large series of patients surgically treated for pheochromocytoma, J Intern Med, 258, 55, 10.1111/j.1365-2796.2005.01504.x

Williams, 2003, Phaeochromocytoma—views on current management, Eur J Surg Oncol, 29, 483, 10.1016/S0748-7983(03)00071-4

Russell, 1998, The preoperative management of phaeochromocytoma, Anaesth Intensive Care, 26, 196, 10.1177/0310057X9802600212

Mannelli, 2006, Management and treatment of pheochromocytomas and paragangliomas, Ann N Y Acad Sci, 1073, 405, 10.1196/annals.1353.044

Bravo, 2002, Pheochromocytoma: An approach to antihypertensive management, Ann N Y Acad Sci, 970, 1, 10.1111/j.1749-6632.2002.tb04408.x

Prys-Roberts, 2000, Phaeochromocytoma—recent progress in its management, Br J Anaesth, 85, 44, 10.1093/bja/85.1.44

Steinsapir, 1997, Metyrosine and pheochromocytoma, Arch Intern Med, 157, 901, 10.1001/archinte.1997.00440290087009

Kanto, 1985, Current status of labetalol, the first alpha- and beta-blocking agent, Int J Clin Pharmacol Ther Toxicol, 23, 617

Pacak, 2007, Preoperative management of the pheochromocytoma patient, J Clin Endocrinol Metab, 92, 4069, 10.1210/jc.2007-1720

Sugano, 1984, [Malignant pheochromocytoma: Blood pressure controlled by labetalol], Nippon Hinyokika Gakkai Zasshi, 75, 523

Rosei, 1976, Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol, Br J Clin Pharmacol, 3, 809

Elliott, 1986, Clinical pharmacological studies with doxazosin, Br J Clin Pharmacol, 21, 27S, 10.1111/j.1365-2125.1986.tb02850.x

Bravo, 1997, Pheochromocytoma, Curr Ther Endocrinol Metab, 6, 195

Lehmann, 1983, Hemodynamic effects of calcium antagonists. Review, Hypertension, 5, II66, 10.1161/01.HYP.5.4_Pt_2.II66

Proye, 1989, Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: Hemodynamics and free catecholamine assays in ten consecutive patients, Surgery, 106, 1149

Engelman, 1968, Biochemical and pharmacologic effects of alpha-methyltyrosine in man, J Clin Invest, 47, 577, 10.1172/JCI105754

Brogden, 1981, α-methyl-p-tyrosine: A review of its pharmacology and clinical use, Drugs, 21, 81, 10.2165/00003495-198121020-00001

Hengstmann, 1979, Malignant pheochromocytoma. Effect of oral alpha-methyl-p-tyrosine upon catecholamine metabolism, Klin Wochenschr, 57, 351, 10.1007/BF01476565

Gumbs, 2006, Laparoscopic adrenalectomy, Best Pract Res Clin Endocrinol Metab, 20, 483, 10.1016/j.beem.2006.07.010

Shen, 2004, Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas, Surgery, 136, 1129, 10.1016/j.surg.2004.05.058

Ippolito, 2008, Safety of laparoscopic adrenalectomy in patients with large pheochromocytomas: A single institution review, World J Surg, 32, 840, 10.1007/s00268-007-9327-5

Soon, 2008, Laparoscopic surgery is safe for large adrenal lesions, Eur J Surg Oncol, 34, 67, 10.1016/j.ejso.2007.03.007

van Heerden, 1990, Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s), World J Surg, 14, 325, 10.1007/BF01658516

Solorzano, 2007, Outcomes of pheochromocytoma management in the laparoscopic era, Ann Surg Oncol, 14, 3004, 10.1245/s10434-007-9489-2

Dimas, 2007, Feasibility of laparoscopic adrenalectomy for large pheochromocytomas, JSLS, 11, 30

Lee, 1996, Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma, Surgery, 120, 1064, 10.1016/S0039-6060(96)80056-0

Jansson, 2006, Treatment of bilateral pheochromocytoma and adrenal medullary hyperplasia, Ann N Y Acad Sci, 1073, 429, 10.1196/annals.1353.046

Yip, 2004, Surgical management of hereditary pheochromocytoma, J Am Coll Surg, 198, 525, 10.1016/j.jamcollsurg.2003.12.001

Snavely, 1983, Selective down-regulation of adrenergic receptor subtypes in tissues from rats with pheochromocytoma, Endocrinology, 113, 354, 10.1210/endo-113-1-354

Meeke, 1985, Phaeochromocytoma removal and postoperative hypoglycaemia, Anaesthesia, 40, 1093, 10.1111/j.1365-2044.1985.tb10608.x

Plouin, 1997, Tumor recurrence and hypertension persistence after successful pheochromocytoma operation, Hypertension, 29, 1133, 10.1161/01.HYP.29.5.1133

DeLellis, 2004, WHO Classification of Tumours—Pathology and Genetics of Tumours of Endocrine Organs, 147

Pattarino, 1996, The diagnosis of malignancy in phaeochromocytoma, Clin Endocrinol (Oxf), 44, 239, 10.1046/j.1365-2265.1996.657475.x

Brouwers, 2005, Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma, Endocr Relat Cancer, 12, 263, 10.1677/erc.1.00913

Chrisoulidou, 2007, The diagnosis and management of malignant phaeochromocytoma and paraganglioma, Endocr Relat Cancer, 14, 569, 10.1677/ERC-07-0074

Helman, 1989, Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma, J Clin Oncol, 7, 1720, 10.1200/JCO.1989.7.11.1720

Gimenez-Roqueplo, 2003, Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas, Cancer Res, 63, 5615

Nativ, 1992, The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma, Cancer, 69, 2683, 10.1002/1097-0142(19920601)69:11<2683::AID-CNCR2820691110>3.0.CO;2-M

Brouwers, 2006, Gene expression profiling of benign and malignant pheochromocytoma, Ann N Y Acad Sci, 1073, 541, 10.1196/annals.1353.058

Thouennon, 2007, Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy, J Clin Endocrinol Metab, 92, 4865, 10.1210/jc.2007-1253

O'Riordain, 1996, Clinical spectrum and outcome of functional extraadrenal paraganglioma, World J Surg, 20, 916, 10.1007/s002689900139

John, 1999, Pheochromocytomas: Can malignant potential be predicted?, Urology, 53, 679, 10.1016/S0090-4295(98)00612-8

Manger, 2004, Pheochromocytoma: Diagnosis and management update, Curr Hypertens Rep, 6, 477, 10.1007/s11906-004-0044-2

Sisson, 2006, Courses of malignant pheochromocytoma: Implications for therapy, Ann N Y Acad Sci, 1073, 505, 10.1196/annals.1353.053

Eisenhofer, 2004, Malignant pheochromocytoma: Current status and initiatives for future progress, Endocr Relat Cancer, 11, 423, 10.1677/erc.1.00829

Eisenhofer, 2004, Biochemical diagnosis of pheochromocytoma, Front Horm Res, 31, 76, 10.1159/000074659

Kebebew, 1998, Benign and malignant pheochromocytoma: Diagnosis, treatment, and follow-up, Surg Oncol Clin N Am, 7, 765, 10.1016/S1055-3207(18)30244-8

Pacak, 2001, Radiofrequency ablation: A novel approach for treatment of metastatic pheochromocytoma, J Natl Cancer Inst, 93, 648, 10.1093/jnci/93.8.648

Takahashi, 1999, Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization, Intern Med, 38, 349, 10.2169/internalmedicine.38.349

Loh, 1997, The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients, J Endocrinol Invest, 20, 648, 10.1007/BF03348026

Shapiro, 2001, Radioisotope diagnosis and therapy of malignant pheochromocytoma, Trends Endocrinol Metab, 12, 469, 10.1016/S1043-2760(01)00492-1

Kaltsas, 2005, Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues, Endocr Relat Cancer, 12, 683, 10.1677/erc.1.01116

Averbuch, 1988, Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine, Ann Intern Med, 109, 267, 10.7326/0003-4819-109-4-267

Scholz, 2007, Clinical review: Current treatment of malignant pheochromocytoma, J Clin Endocrinol Metab, 92, 1217, 10.1210/jc.2006-1544

Schlumberger, 1992, Malignant pheochromocytoma: Clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases, J Endocrinol Invest, 15, 631, 10.1007/BF03345807

Nakane, 2003, Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline, Ann Oncol, 14, 1449, 10.1093/annonc/mdg358

Iwabuchi, 1999, Palliative chemotherapy for malignant pheochromocytoma: Symptomatic palliation of two cases, Intern Med, 38, 433, 10.2169/internalmedicine.38.433

Kulke, 2006, Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors, J Clin Oncol, 24, 401, 10.1200/JCO.2005.03.6046

Gross, 2006, The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-Kit or PDGF-R, Endocr Relat Cancer, 13, 535, 10.1677/erc.1.01124

Sausville, 2003, Clinical development of 17-allylamino, 17-demethoxygeldanamycin, Curr Cancer Drug Targets, 3, 377, 10.2174/1568009033481831

Bornstein, 2006, Genetic testing in pheochromocytoma: Increasing importance for clinical decision making, Ann N Y Acad Sci, 1073, 94, 10.1196/annals.1353.010

Favier, 2005, Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency, Horm Res, 63, 171

Dahia, 2006, Evolving concepts in pheochromocytoma and paraganglioma, Curr Opin Oncol, 18, 1, 10.1097/01.cco.0000198017.45982.06

Sisson, 1999, Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy, Am J Clin Oncol, 22, 364, 10.1097/00000421-199908000-00008

Kappes, 2006, ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells, J Surg Res, 133, 42, 10.1016/j.jss.2006.02.002

Kappes, 2007, Lithium ions: A novel treatment for pheochromocytomas and paragangliomas, Surgery, 141, 161, 10.1016/j.surg.2006.12.005

Adler, 2008, Histone deacetylase inhibitors upregulate notch1 and inhibit growth in pheochromocytoma cells, Surgery

Maher, 2002, The pressure rises: Update on the genetics of phaeochromocytoma, Hum Mol Genet, 11, 2347, 10.1093/hmg/11.20.2347

Schiavi, 2005, Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene, JAMA, 294, 2057, 10.1001/jama.294.16.2057

Thompson, 2002, Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases, Am J Surg Pathol, 26, 551, 10.1097/00000478-200205000-00002